- Title
- Safety and Tolerability of Lete-cel in NSCLC—Reply
- Creators
- Mehmet Altan - The University of Texas MD Anderson Cancer CenterGilberto Lopes - University of Miami Health SystemT. Jeroen N. Hiltermann - University Medical Center GroningenRamaswamy Govindan - Washington University in St. LouisLiza C. Villaruz - UPMC Hillman Cancer CenterEmiliano CalvoMartin J. Edelman - Fox Chase Cancer CenterMuhammad Furqan - University of IowaJoel Neal - Stanford UniversityEnriqueta Felip - Vall d'Hebron Hospital UniversitariJennifer W. Carlisle - Emory UniversityJohn V. Heymach - The University of Texas MD Anderson Cancer CenterRóisín Eilish O’Cearbhaill - Kettering UniversityMarjorie Zauderer - Kettering UniversityMichael Chisamore - MerckEllie Corigliano - GlaxoSmithKlineIoanna Eleftheriadou - GlaxoSmithKlineStefan Zajic - GlaxoSmithKlineBen Jenkins - GlaxoSmithKlineSophia Goodison - GlaxoSmithKlineSunil Suchindran - GlaxoSmithKlineNatalia Ramos-Hernandez - GlaxoSmithKlineNidale Tarek - GlaxoSmithKlineAdam J. Schoenfeld - Memorial Sloan Kettering Cancer Center
- Publication Details
- Clinical cancer research, Vol.31(9), pp.1810-1811
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991032654916502976
Journal article
Safety and Tolerability of Lete-cel in NSCLC—Reply
Clinical cancer research, Vol.31(9), pp.1810-1811
2025-05-01
Metrics
3 Record Views